Investigation of antiviral treatment for symptomatic congenital cytomegalovirus infection

Investigation of antiviral treatment for symptomatic congenital cytomegalovirus infection - antiviral treatment for congenital CMV infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019464

Enrollment

Registered

2015-10-23

Start date

2009-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital cytomegalovirus infection

Interventions

oral VGCV at 32mg/kg/day (b.i.d) for 6 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with congenital CMV-related SNHL or CMV-related clinical abnormalities other than SNHL

Exclusion criteria

Exclusion criteria: < 1 month of age < 32 weeks gestation < 1800g

Design outcomes

Primary

Measure	Time frame
auditory brainstem response	—

Secondary

Measure	Time frame
levels of CMV DNA in blood	—

Countries

Japan

Contacts

Public ContactYoshinori Ito

Nagoya University Graduate School of Medicine Department of Pediatrics

yoshi-i@med.nagoya-u.ac.jp052-744-2974

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026